Myeloid leukemias are among the most aggressive blood cancers and have low survival rates. Today, leukemia patients undergo ...

A study demonstrates that the 'previous state' of blood stem cells plays a decisive role in the subtype of leukemia that develops. The new technique, called STRACK, allows monitoring of the evolution ...

▎药明康德内容团队编辑（来源：武汉大学）急性髓系白血病（AML）是一种由造血干/祖细胞遗传异常引发的血液系统恶性肿瘤，其致病因素主要包括染色体易位和基因突变等遗传变异。除急性早幼粒细胞白血病外，AML普遍存在治疗手段有限、复发率高、死亡率高等问题，导 ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment ContinuesPromising Data, including a 59% Stable ...

Leukemic stem cells (LSCs) and stemness signatures contribute to minimal residual disease in patients with acute myeloid leukemia (AML), which is associated with an increased risk of relapse. The ...

DNA and RNA epigenetics, once thought to be separate, have now been found to work together to fine-tune gene expression.

Treatment with tuspetinib in combination with Venclexta and Vidaza in newly diagnosed acute myeloid leukemia showed safety ...

Aptose Biosciences advances its Phase 1/2 TUSCANY trial, escalating tuspetinib dosing after a favorable safety review. Enrollment continues across U.S. sites.